Bioorganic and Medicinal Chemistry Letters p. 349 - 352 (2019)
Update date:2022-08-17
Topics:
Zhou, Ruolan
Fang, Shaoyu
Zhang, Minmin
Zhang, Qingsen
Hu, Jian
Wang, Mingping
Wang, Chongqing
Zhu, Ju
Shen, Aijun
Chen, Xin
Zheng, Canhui
Multiple myeloma (MM) is the second most common haematological malignancy. Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action. Therefore novel drugs are in urgent need in clinic. Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions. In this study, a series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized. Among them, compounds 7e–7g showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously. They also displayed good growth inhibitory activities against human MM cell line RPMI-8226, which proved their potential value for the treatment of multiple myeloma.
View MoreZhejiang Golden-Shell Pharmaceutical Co.,Ltd.
Contact:+86-576-87501888 / 87501988
Address:No.89 Zhongxing Road. Li'ao, Yuhuan, Zhejiang, China
Contact:+86-15995924277
Address:WuZhongOu suzhou new south road 89
Tangshan Wisdom Trading Co.,Ltd
Contact:86 315 2222979
Address:No.41 BeiXinXi Road, Yangguang building 1-1102 , Tangshan, Hebei, China
Hangzhou Donglou Bio-nutrient Co., Ltd.
Contact:+86-571-82225795,13967112289
Address:Louta Town, Xiaoshan,Hangzhou,Zhejiang
Jiangsu Jiuri Chemical Co.,Ltd.
Contact:+86-519-82118868
Address:Tianwang Town, Jurong City, Jiangsu Province, China
Doi:10.1021/acs.joc.0c00286
(2020)Doi:10.1016/S0040-4039(01)98386-8
(1970)Doi:10.1039/c3ra45749d
(2014)Doi:10.1016/S0960-894X(01)00495-4
(2001)Doi:10.1021/jo01050a509
(1962)Doi:10.1007/BF00952224
()